Dimanche, 4 juillet 2021 01:00
Coup d oeil sur cet article
La psychothérapie psychédélique est de plus en plus considérée par les experts comme un traitement d’avenir pour soigner des patients à court d’options qui souffrent de dépression, d’alcoolisme ou de stress post-traumatique.
«Je crois que ce type de thérapie deviendra la norme dans le futur. Ce n’est pas pour tout le monde, mais pour ceux qui se qualifient, ça change complètement la donne», affirme Houman Farzin, un docteur québécois qui s’intéresse à ces traitements.
De fait, des drogues hallucinogènes comme le LSD, l’ecstasy (MDMA) et les champignons magiques sont de nouveau étudiées le plus sérieusement du monde par les scientifiques pour leurs vertus thérapeutiques.
/CNW/ - Diamond Therapeutics Inc. ("Diamond"), a leading psychedelic drug development company focused on low-dose therapies for mental health, has entered into.
Boston Suburbs Look To Decriminalize Natural Psychedelics
That includes psilocybin mushrooms, ayahuasca, the peyote cacti and the iboga plant.
On Wednesday, Cambridge, Massachusetts voted 8 to 1 in its City Council to decriminalize “all Entheogenic Plants and plant-based compounds,” making them a lowest law enforcement priority (h/t Marijuana Moment).
Three weeks earlier, Somerville passed a similar measure with unanimous votes from its City Council.
Cambridge and Somerville have a population of over 105,000 and 80,000, respectively.
The Cambridge resolution makes notice of the fact that the so-called War on Drugs “has historically led to unnecessary penalization, arrest, and incarceration of vulnerable people, particularly people of color and of limited financial means.”
Share this article
TORONTO, Feb. 4, 2021 /PRNewswire/ - Diamond Therapeutics Inc. (
Diamond ), a leading psychedelic drug development company focused on low-dose therapies for mental health, has entered into an agreement with McGill University for the exclusive use of Dr. Gabriella Gobbi s groundbreaking studies with lysergic acid diethylamide (LSD), its mechanism of action on the brain, and its potential for use at low doses in the treatment of mental health disorders.
The agreement provides Diamond with access to the technology, data and intellectual property developed by Dr. Gobbi and postdoctoral fellow Danilo De Gregorio, PharmD, Ph.D. and published in the Proceedings of the National Academy of Sciences of the United States of America. The work investigates for the first time the mechanism of action behind LSD s effect on social interactions. The findings suggest that psychedelics could play a role in treating diseases characterized by social impairment, such as autism spe